HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Nature Biotechnology editorial asks whether GLP-1 drugs are the first longevity drugs

Louis Nervegna · Nov 24, 2025 · ♥ 5 reactions · 11 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Aging & longevity
AI summary & key facts

Louis shares an editorial reporting that Novo Nordisk and Eli Lilly speakers proposed GLP-1 drugs might be the first longevity drugs, given benefits across heart attack, stroke, heart failure, PAD, kidney and liver disease.

Are glp1 agonists the first longevity drugs? The miracles of calorie restriction in humans.

#glp1HD #calorierestrictionHD #longevityHD #agingHD

Research cited

Editorial: Are GLP-1s the first longevity drugs?

As pharma ramps up efforts on disorders of aging, a new era of disease prevention comes into focus.

At the August meeting of Aging Research and Drug Discovery in Copenhagen, two speakers from Novo Nordisk and Eli Lilly electrified the audience by proposing that GLP-1 receptor agonists (GLP-1s) — the blockbuster obesity and diabetes therapies — may be the first longevity drugs. Beyond the unprecedented efficacy of GLP-1s in obesity and type 2 diabetes, evidence that they improve comorbidities has been accumulating at an impressive pace in recent years. From heart attack, stroke, heart failure and peripheral artery disease, to kidney and liver disease, to knee osteoarthritis and obstructive sleep apnea, the cascade of news about approved indications and major clinical studies has sparked media talk of a wonder drug that should be added to the water supply. Clinical elucidation of all that these drugs can and cannot do will take careful study over many years, but early signs of their benefits for several chronic diseases of aging are already unmistakable — in some people with metabolic disease. For everyone else, clinical data are lacking. Yet the rapprochement between the two big GLP-1 drugmakers and the longevity field signals a shift toward drugs that have broad impact on multiple pathological processes and, eventually, a future of preventive medicine in which early screening and long-acting therapies ward off chronic diseases before they start.

Longevity drugs hold unique promise and face singular challenges compared with today’s biopharmaceuticals. Because aging is the biggest risk factor for diseases that manifest later in life — heart disease, stroke, cancer, Alzheimer’s disease, arthritis and many others — drugs that targeted mechanisms of aging could in principle prevent scores of illnesses at once. Aging itself is not usually considered a disease. At a bird’s-eye view, it appears to be a gradual systemic decline arising from a competition between damaging forces and the body’s processes of repair and regeneration. Sources of damage include general physical factors such as UV radiation and lifestyle factors such as diet, exercise, sleep, stress, pollution, social connections and healthcare accessibility. But decades of research to understand, measure and manipulate aging has brought the field to the cusp of effective molecularly targeted drugs.

Landmark studies in the 1990s set aging on a scientific foundation by showing that lifespan in animals depends on particular genes and can be altered by genetic modification. Subsequent research unraveled conserved aging-associated molecular pathways, leading to the 2013 classification of 9 hallmarks of aging(1), later expanded to 12 and then 14(ref. 2). The hallmarks include damage at the genetic, epigenetic, protein, mitochondrial, cellular, extracellular and systemic levels. They are intricately interrelated in a complex web, share molecular pathways and are not necessarily feasible to measure. In parallel, ’omics data and machine learning have been used to build computational models and aging clocks that make predictions about biological age, organ-specific age and mortality, as well as aspects of aging relevant to drug development, such as drug targets and aging biomarkers, which could become validated as surrogate endpoints.

In 2006, Shinya Yamanaka’s discovery that a few transcription factors can reprogram adult differentiated cells to an embryonic state showed that cellular age is plastic and that cells can be rejuvenated. This finding has been explored as an anti-aging strategy through the concept of ‘partial reprogramming’ — enough to make cells younger but without going all the way back to pluripotency, an approach that was recently applied to mitigate the aging mechanism of mesenchymal drift(3).

The term ‘longevity’ is used in several ways, inviting confusion, but the Longevity Biotechnology Association has provided useful guidelines(4) for the field. By their definition, a longevity drug targets at least one aging pathway, is “capable of treating or preventing multiple age-related diseases,” and thereby improves healthspan, “the period of life a person spends in good health.” Although such a drug would be expected to extend life by lessening chronic disease, surveys show that the public cares much more about improved well-being and vitality than about longer lifespan. A focus on healthspan is also more realistic because the size, length and cost of lifespan trials (without top-notch surrogate endpoints) are impractical.

No gerotherapeutic has been approved, although some approved drugs might qualify as such if appropriately tested(5). The US Food and Drug Administration (FDA) does not recognize aging as a disease indication and has no regulatory pathway for anti-aging interventions. For now, anti-aging clinical studies are framed in terms of single age-related diseases. Drug candidates tested in humans to date, such as anti-inflammatory drugs, sirtuin activators, senolytics, NAD+ precursors, metformin and rapamycin, have not yet been shown to slow aging or the onset of age-related diseases. The failure of the $720 million sirtuin activator program acquired by GlaxoSmithKline from Sirtris Pharmaceuticals was a notable setback in the field. Compared with previous anti-aging candidates, GLP-1s are much more effective as metabolic drugs, and there are vastly more human data for them.

The Copenhagen aging conference was not the first time that GLP-1s and aging had been discussed or that pharma had ventured into the longevity space. But the appearance of the two distinguished scientific leaders, Lotte Bjerre Knudsen from Novo Nordisk and Andrew Adams from Eli Lilly, discussing the longevity potential of these medicines before the aging research community was seen by many in attendance as momentous. The talks described emerging capabilities for preventive medicine and the benefits of GLP-1s for different conditions and organs, including pancreas, intestine, heart, blood vessels, brain, kidney and liver, and for all-cause mortality in some trials.

For people with obesity or type 2 diabetes, clinical trial data and real-world evidence have shown clearly that GLP-1s ameliorate some age-related comorbidities in those who are at high risk of them to start with. Improvements in cardiovascular outcomes and all-cause mortality were seen both in type 2 diabetes(6) and in obesity without diabetes(7,8 ). Only about a third of the cardiovascular benefits in the latter trial were weight loss-dependent(9), suggesting other underlying mechanisms, such as anti-inflammation, that may be broadly relevant outside of overweight and obesity. However, the caveat that benefits for comorbidities seem to accrue mainly to people at high risk of them is important when considering the generalizability of the effects. Efficacy is harder to detect in people at lower risk, smaller effect sizes require larger trials, and at some point the risk–benefit ratio becomes too marginal to pursue.

How well GLP-1s will fulfill the longevity drug criteria of treating or preventing multiple diseases of aging remains to be seen. Clinical trials of these medicines in healthy people have not been published and may not be conducted for some time. But trials are beginning in diseases other than obesity and type 2 diabetes. The inflammation-lowering and immunomodulatory effects of GLP-1s suggest a potential broad scope, including cardiovascular, neuroinflammatory and autoimmune diseases. Weight loss-independent antifibrotic effects were found to contribute to benefits of GLP-1s in metabolic dysfunction-associated steatohepatitis (MASH)(10). The highly anticipated evoke and evoke+ phase 3 trials(11) are evaluating the GLP-1 semaglutide in early-stage symptomatic Alzheimer’s disease. Encouraging results(12) for dementia with GLP-1s have been seen in people with type 2 diabetes, which raises dementia risk. The evoke studies, which bypassed phase 2, include a large number of participants without type 2 diabetes. Positive results would support the argument that GLP-1s have pan-aging effects.

Investigating the effectiveness of GLP-1s for longevity will involve exploring variables such as disease indications, analogs, formulations, dosing, individual hormone agonist combinations, biomarkers, and approaches to minimize side effects. A more speculative gene-therapy approach that aims to provide meal-regulated GLP-1 secretion is also being pursued. Patients on GLP-1s today discontinue them at high rates for various reasons, including side effects and cost. Adherence is also a concern with preventive medicines, such as statins, which do not make a tangible difference in how people feel. Gerotherapeutics are more likely to succeed if they are safe and effective over decades, affordable, preferably long-acting, and used in a precision medicine approach.

In the race to aging-relevant indications for GLP-1s, data science is crucial for scrutinizing clinical trial data and making sense of the rapidly expanding, longitudinal real-world data from millions of patients taking these drugs, who have different comorbidities and who may respond differently over time to the same therapy. These analyses can shed light on the mechanisms underlying GLP-1s’ effects, help to optimize trial design to efficiently explore the most promising ideas, and lead to treatment protocols better tailored to individual patients.

The escalating interest in longevity at Novo Nordisk, Eli Lilly and other biopharma companies is not limited to GLP-1s. Many other strategies are being looked at. Tamping down ‘inflammaging’, the chronic inflammation that underlies diseases of aging, by inhibiting inflammasome targets such as NLRP3 could be broadly beneficial for healthspan. Another promising inflammaging target is the cGAS–STING pathway. A different direction is drugs that mimic apelin, a signaling molecule induced by exercise (‘exerkine’). Apelin receptor activation in animals inhibits aging and boosts muscle growth, of particular importance in older people with frailty. Additional targets of interest to enhance healthspan include myostatin and ACTII receptor for muscle wasting, the glucocorticoid receptor NR3C1 for metabolism, the cytokine interleukin-11 for fibrosis, PHD1/2 for anemia and barrier repair, and orexin receptors for insomnia.

US life expectancy is 79.3 years, six years below Hong Kong’s, three years below Canada’s and down at number 63 on a ranked list by country or region. US expenditures on chronic diseases of aging run into the trillions of dollars annually. Medicines that targeted root causes of these diseases to delay their onset or prevent them entirely would be transformative for healthcare and human well-being.

It has been 20 years since the first GLP-1 was FDA-approved, for type 2 diabetes. Since then, new indications have been slowly added one by one for people with type 2 diabetes or elevated BMI — weight loss, cardiovascular disease, sleep apnea, chronic kidney disease and MASH. The TAME(13) aging trial of metformin proposed a more efficient approach: a composite outcome of time to any of several distinct chronic diseases (cardiovascular disease, cancer and dementia). Composite outcomes have the added advantage that, if the results all move in the same direction, statistical significance can be detected in smaller populations. At a time of fast-moving, AI-powered research, FDA leadership on innovative trial designs that are better suited to the healthspan model would speed approval of gerotherapeutics, save limited resources allotted to clinical trials, and incentivize industry in this area. A regulatory framework for healthspan products in the form of a Congressional bill, the THRIVE Act, has been proposed by a team led by a former FDA official who approved the first statin and metformin.

The longevity researcher and drug developer Alex Zhavoronkov has observed, “Aging is life. Life is aging.” There is no cure for mortality, but much can be done to make our lives longer in health and happiness.

References

  1. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Cell The Hallmarks of Aging (Cell, 2013) (2013).
  2. Kroemer, G. et al. Cell From geroscience to precision geromedicine: Understanding and managing aging (Cell, 2025) (2025).
  3. Lu, J. Y. et al. Cell Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming (Cell, 2025) (2025).
  4. Boekstein, N. et al. Nat. Biotechnol. Defining a longevity biotechnology company (Nat Biotechnol, 2023) (2023).
  5. Kulkarni, A. S. et al. Aging Cell Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed… (Aging Cell, 2022) (2022).
  6. Sattar, N. et al. Lancet Diabetes Endocrinol. 9, 653–662 (2021).
  7. Lincoff, A. M. et al. New Engl. J. Med. 389, 2221–1132 (2023).
  8. Scirica, B. M. et al. J. Am. Coll. Cardiol. 84, 1632–1642 (2024).
  9. Deanfield, J. et al. Lancet Link to doi.org (doi.org) (2025).
  10. Jara, M. et al. Nat. Med. 31, 3128–3140 (2025).
  11. Cummings, J. L. et al. Alzheimers Res. Ther. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3… (Alzheimers Res Ther, 2025) (2025).
  12. Nørgaard, C. H. et al. Alzheimers Dement. Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia:… (A&D Transl Res & Clin Interv, 2022) (2022).
  13. Barzilai, N., Crandall, J. P., Kritchevsky, S. B. & Espeland, M. A. Cell Metab. Metformin as a Tool to Target Aging (Cell Metabolism, 2016) (2016).

Nat. Biotechnol. 43, 1741–1742 (2025) | DOI: 10.1038/s41587-025-02932-1
Published: 12 November 2025

← newer: Criticism of a video's protein claimsolder: Five lifestyle factors cut heart disease 82% and diabetes 90 →